UN Weekly: Black Blood Applicants Surge Past 5,000
Luna, late October 2125 ES. More than one hundred individuals from the original 2124 human trial cohort of Dr. Klaus Jäger’s melanin-integrated hemoprotein treatment — known informally as “black blood” (MHA-1) — have now reported that they no longer require anti-radiation medication of any kind, commercial or the UN-issued SVR-3 standard in continuous use since 2068.
That standard has held for over half a century. SVR-3, developed under Dr. Taisiya Bondarenko’s Svarog Programme, extended safe EVA rotation length from roughly 90 to 140 days and cut acute radiation syndrome incidence by 61% among treated crew — a genuine advance, but one its own developer was careful never to overstate. Bondarenko’s 2068 interim report closed with a line still quoted in radiation-medicine circles today: “We have not solved radiation. We have bought time against it, in a currency that does not renew the way a fuel tank does. Anyone who tells a crew otherwise is selling something.” MHA-1 is, for the first time, a claim of a different kind — not managing exposure, but removing the need to manage it at all.
Uptake
As of 26 October 2125 ES, 5,278 applicants have registered interest in the treatment since the 2124 human trial phase began — a figure UN Weekly confirmed directly with Dome 4 administration. Public reaction has ranged from cautious to enthusiastic; one applicant, asked why they’d signed up, offered a reason with no relation to radiation tolerance at all: “Honestly? Black blood looks so cool.” Cost has not been a barrier to interest — the treatment is available for as little as 10 UN credits at the public clinic operating out of Guanghan Base, well within reach for most Luna and Ceres residents.
What Isn’t Known Yet
No party involved — Dome 4, the UN Office for Colonial Development, or Jäger himself in his original 2121 interview — has claimed long-term safety data exists, because it doesn’t yet: the oldest human recipients are barely a year into treatment. Whether “no longer needing SVR-3” holds up over a full career’s radiation exposure, rather than a single year of it, remains an open question by the numbers alone.
The Heritable Question
Separately, and more quietly, Dome 4 confirmed that 254 individuals consented in early 2125 to a germline modification variant of the treatment — engineered so that MHA-1 expression could be inherited by offspring rather than administered per-individual. No adverse effects have been reported in that cohort to date. Dome 4 declined to characterize the program’s long-term ethical or regulatory framework beyond confirming its existence, and UN Weekly could not obtain comment from the Article Four Coalition, which has not yet issued a public position on heritable radioprotective modification specifically, as distinct from embodied cognition.
See Also
- Jäger et al., MHA-1 — Black Blood Paper (2121)
- Luna Interplanetary News: Jäger Black Blood Interview (2121)
- Bondarenko, Svarog Programme Interim Report — SVR-3 (2068)
- Dr. Klaus Jäger
- Dr. Taisiya Bondarenko
Sources
- Dome 4 administration, applicant registration figures (26 October 2125)
- Bondarenko, Svarog Programme Interim Report — SVR-3 Crewed Trial Results (2068)
- Jäger et al., Melanized Hemoprotein Analogue Confers Radioprotection and Enhanced Oxygen Transport (2121)
- UN Weekly staff reporting and applicant interviews